Logo_final_color.png
Cybrexa Therapeutics宣布NAR Cancer刊发经同行评议的相关论文
June 09, 2021 09:12 ET | Cybrexa Therapeutics
康涅狄格州纽黑文, June 09, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics是一家致力于肿瘤学的生物科技公司,通过其alphalex™多肽药物偶联物(PDC)肿瘤靶向平台开发新一代疗法。该公司今天宣布,NAR Cancer发表了有关Cybrexa候选先导化合物CBX-12的经同行评议研究。NAR...
Logo_final_color.png
Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer
June 08, 2021 10:41 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., June 08, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
Logo_final_color.png
Cybrexa Therapeutics任命Stephen Basso为首席财务官
May 20, 2021 10:49 ET | Cybrexa Therapeutics
康涅狄格州纽黑文, May 20, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics是一家专注于肿瘤学的生物技术公司,通过其alphalex™多肽药物偶联(PDC)肿瘤靶向平台开发新类别药物。该公司今天宣布任命制药和金融服务行业资深人士Stephen Basso为首席财务官。 ...
Logo_final_color.png
Cybrexa Therapeutics Appoints Stephen Basso as Chief Financial Officer
May 20, 2021 07:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate...
Logo_final_color.png
Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors
May 10, 2021 07:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate...
Logo_final_color.png
Cybrexa Therapeutics宣布用于治疗晚期或转移性难治实体肿瘤的CBX-12(alphalex™-exatecan )1/2期临床试验完成首位患者给药
May 10, 2021 07:00 ET | Cybrexa Therapeutics
康涅狄格州纽黑文, May 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics是一家致力于肿瘤学的生物科技公司,通过其alphalex™多肽药物偶联物 (PDC)肿瘤靶向平台开发新型疗法。该公司今天宣布,一项评估其候选先导化合物CBX-12(alphalex™-exatecan)的1/2期临床试验已完成首位患者给药。 ...
Logo_final_color.png
Cybrexa Therapeutics的CBX-12(alphalex™-exatecan)新药临床试验申请获FDA批准
March 22, 2021 07:00 ET | Cybrexa Therapeutics
康涅狄格州纽黑文, March 22, 2021 (GLOBE NEWSWIRE) -- 以肿瘤治疗为重点并通过其alphalex™多肽药物偶联(PDC)肿瘤靶向平台开发新一代疗法的生物科技公司Cybrexa Therapeutics今天宣布,美国食品和药品管理局(FDA)已批准了该公司先导治疗剂候选药物CBX-12(alphalex™-依沙替康)的新药临床试验(IND)申请。 ...
Logo_final_color.png
Cybrexa Therapeutics Receives Green Light from FDA on Investigational New Drug Application for CBX-12 (alphalex™-exatecan)
March 22, 2021 07:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
Logo_final_color.png
Cybrexa Therapeutics完成2500万美元B轮融资
March 10, 2021 07:00 ET | Cybrexa Therapeutics
-所获资金将推进公司领先项目进入到临床试验- 康涅狄格州纽黑文, March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics是一家专注于肿瘤学的生物技术公司,通过其alphalex™多肽药物偶联(PDC)肿瘤靶向平台开发新类别药物。该公司今天宣布已完成其2500万美元的B轮融资。参与此轮融资的包括HighCape...
Logo_final_color.png
Cybrexa Therapeutics Closes $25 Million Series B Financing
March 10, 2021 07:00 ET | Cybrexa Therapeutics
-Proceeds will advance the company’s lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company...